Role of the E45K-reduced folate carrier gene mutation in methotrexate resistance in human leukemia cells

Leukemia

Volumn 16, Issue 12, 2002, Pages 2379-2387

  Gifford, A J ^a   Haber, M ^a   Witt, T L ^b   Whetstine, J R ^b   Taub, J W ^b   Matherly, L H ^b   Norris, M D ^a  

^a CHILDREN S CANCER INSTITUTE AUSTRALIA FOR MEDICAL RESEARCH   (Australia)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acute lymphoblastic leukemia; Drug resistance; Reduced folate carrier gene; Trimetrexate

Indexed keywords

FOLIC ACID; FOLIC ACID ANTAGONIST; FOLINIC ACID; GLUTAMIC ACID; LYSINE; METHOTREXATE; POLYGLUTAMIC ACID; RALTITREXED; REDUCED FOLATE CARRIER; TRIMETREXATE; TRIMETREXATE GLUCURONATE;

ACUTE LYMPHOBLASTIC LEUKEMIA; AMINO ACID SUBSTITUTION; ARTICLE; BINDING AFFINITY; CHILDHOOD LEUKEMIA; CODON; CONTROLLED STUDY; CYTOTOXICITY TEST; ENZYME SUBSTRATE; GENE MUTATION; GENE OVEREXPRESSION; GENETIC IDENTIFICATION; GENETIC TRANSFECTION; HETEROZYGOTE; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MEMBRANE TRANSPORT; NULL CELL; POINT MUTATION; PRIORITY JOURNAL; TREATMENT FAILURE; WILD TYPE;

EID: 0036936617     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402655     Document Type: Article

References (43)

1. Poplack DG. Acute lymphoblastic leukemia. In: Pizzo PA, Poplack DG (eds). Principles and Practice of Pediatric Oncology, 2nd edn. JB Lippincott: Philadelphia, 1993, pp 431-481.
2. Pui CH, Evans WE. Acute lymphoblastic leukemia. N Engl J Med 1998; 339: 605-615.
3. Pui CH. Childhood leukemias. N Engl J Med 1995; 332: 1618-1630.
4. Rots MG, Pieters R, Kaspers GJL, Veerman AJP, Peters GJ, Jansen G. Classification of ex vivo methotrexate resistance in acute lymphoblastic and myeloid leukaemia. Br J Haematol 2000; 110: 791-800.
5. Gorlick R, Coker E, Trippett T, Waltham M, Banerjee D, Bertino JR. Intrinsic and acquired resistance to methotrexate in acute leukaemia. N Engl J Med 1996; 335: 1041-1048.
6. Norris MD, Haber M, Kavallaris M, Brian MJ, Lutze LH, White L, Stewart BW. Reduced drug accumulation as the mechanism of extreme clinical resistance to methotrexate in the human T-cell leukemia xenograft, LALW-2. Cancer 1991; 68: 981-987.
7. Trippett T, Schlemmer S, Elisseyeff Y, Goker E, Wachter M, Steinherz P, Tan C, Berman E, Wright JE, Rosowski A, Schweitzer B, Bertino JR. Defective transport as a mechanism of acquired resistance to methotrexate in patients with acute lymphocytic leukemia. Blood 1992; 80: 1158-1162.
8. Gorlick R, Goker E, Trippett T, Steinherz P, Elisseyeff Y, Mazumdar M, Flintoff WF, Bertino JR. Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression. Blood 1997; 89: 1013-1018.
9. Dixon KH, Lanpher BC, Chiu J, Kelley K, Cowan KH. A novel cDNA restores reduced folate carrier activity and methotrexate sensitivity to transport deficient cells. J Biol Chem 1994; 269: 17-20.
10. Moscow JA, Gong M, He R, Sgagias MK, Dixon KH, Anzick SL, Meltzer PS, Cowan KH. Isolation of a gene encoding a human reduced folate carrier (RFC1) and analysis of its expression in transport-deficient, methotrexate-resistant human breast cancer cells. Cancer Res 1995; 55: 3790-3794.
11. Prasad PD, Ramamoorthy S, Leibach FH, Ganapathy V. Molecular cloning of the human placental folate transporter. Biochem Biophys Res Commun 1995; 206: 681-687.
12. Williams FMR, Flintoff WF. Isolation of a human cDNA that complements a mutant hamster cell defective in methotrexate uptake. J Biol Chem 1995; 270: 2987-2992.
13. Wong SC, Proefke SA, Bhushan A, Matherly LH. Isolation of human cDNAs that restore methotrexate sensitivity and reduced folate carrier activity in methotrexate transport-defective Chinese hamster ovary cells. J Biol Chem 1995; 270: 17468-17475.
14. Ferguson PL, Flintoff WF. Topological and functional analysis of the human reduced folate carrier by haemagglutinin epitope insertion. J Biol Chem 1999; 274: 16269-16278.
15. Gifford AJ, Kavallaris M, Madafiglio J, Matherly LH, Stewart BW, Haber M, Norris MD. P-glycoprotein-mediated methotrexate resistance in CCRF-CEM sublines deficient in methotrexate accumulation due to a point mutation in the reduced folate carrier gene. Int J Cancer 1998; 78: 176-181.
16. Jansen G, Mauritz R, Drori S, Sprecher H, Kathmann I, Bunni M, Priest DG, Noordhuis P, Schornagel JH, Pinedo HM, Peters GJ, Assaraf YG. A structurally altered human reduced folate carrier with increased folic acid transport mediates a novel mechanism of antifolate resistance. J Biol Chem 1998; 273: 30189-30198.
17. Tse A, Brigle K, Taylor SM, Moran RG. Mutations in the reduced folate carrier gene which confer dominant resistance to 5,10-dideazatetrahydrofolate. J Biol Chem 1998; 273: 25953-25960.
18. Zhao RB, Assaraf YG, Goldman ID. A reduced folate carrier mutation produces substrate-dependent alterations in carrier mobility in murine leukemia cells and methotrexate resistance with conservation of growth in 5-formyltetrahydrofolate. J Biol Chem 1998; 273: 7873-7879.
19. Zhao R, Assaraf YG, Goldman ID. A mutated murine reduced folate carrier (RFC1) with increased affinity for folic acid, decreased affinity for methotrexate, and an obligatory anion requirement for transport function. J Biol Chem 1998; 273: 19065-19071.
20. Zhao RB, Sharina IG, Goldman ID. Pattern of mutations that results in loss of reduced folate carrier function under antifolate selective pressure augmented by chemical mutagenesis. Mol Pharmacol 1999; 56: 68-76.
21. Sadlish H, Murray RC, Williams FMR, Flintoff WF. Mutations in the reduced-folate carrier affect protein localization and stability. Biochem J 2000; 346: 509-518.
22. Drori S, Jansen G, Mauritz R, Peters GJ, Assaraf YG. Clustering of mutations in the first transmembrane domain of the human reduced folate carrier in GW1843U89-resistant leukemia cells with impaired antifolate transport and augmented folate uptake. J Biol Chem 2000; 275: 30855-30863.
23. Haber M, Gifford AJ, Matherly LH, Norris MD. Transfection of the reduced folate carrier gene into methotrexate-resistant cells alters their resistant phenotype. Proc Amer Assoc Cancer Res 1999; 40: 675-676 (Abstr.)
24. Taylor IW, Slowiaczek P, Freidlander ML, Tattersall MNH. Selective toxicity of a new lipophilic antifolate, BW301U, for methotrexate-resistant cells with reduced drug uptake. Cancer Res 1985; 45: 978-982.
25. Waters K. Australian and New Zealand trials in acute lymphoblastic leukemia of childhood. Int J Pediat Hematol/Oncol 1998; 5: 187-197.
26. Land VJ, Shuster JJ, Crist WM, Ravindranath Y, Harris MB, Krance RA, Pinkel D, Pullen JD. Comparison of two schedules of intermediate-dose methotrexate and cytarabine consolidation therapy for childhood B-precursor cell acute lymphoblastic leukemia: a Pediatric Oncology Group Study. J Clin Oncol 1994; 12: 1939-1945.
27. Matherly LH, Taub JW, Wong SC, Simpson PM, Ekizian R , Williamson M, Buck S, Amylon M, Pullen J, Camitta B, Ravindranath Y. Increased frequency of expression of elevated dihydrofolate reductase in T-cell versus B-precursor acute lymphoblastic leukemia in children. Blood 1997; 90: 578-589.
28. Zhang L, Taub JW, Williamson M, Wong SC, Hukku B, Pullen J, Ravindranath Y, Matherly LH. Reduced folate carrier gene expression in childhood acute lymphoblastic leukemia: relationship to immunophenotype and ploidy. Clin Cancer Res 1998; 4: 2169-2177.
29. Xia F, Liber HL. Electroporation of human lymphoblastoid cells. In: Nickoloff JA (ed.) Methods in Molecular Biology, Vol 48. Humana Press: Totowa, 1995, pp. 151-160.
30. Haber M, Norris MD, Kavallaris M, Bell DR, Davey RA, White L, Stewart BW. Atypical multidrug resistance in a therapy-induced drug-resistant human leukemia cell line (LALW-2): resistance to vinca alkaloids independent of P-glycoprotein. Cancer Res 1989; 49: 5281-5287.
31. Matherly LH, Czajkowski CA, Angeles SM. Identification of a highly glycosylated methotrexate membrane carrier in K562 human erythroleukaemia cells up-regulated for tetrahydrofolate cofactor and methotrexate transport. Cancer Res 1991; 51: 3420-3426.
32. Wong SC, McQuade R, Proefke SA, Bhushan A, Matherly LH. Human K562 transfectants expressing high levels of reduced folate carrier but exhibiting low transport activity. Biochem Pharmacol 1997; 53: 199-206.
33. Wong SC, Zhang L, Proefke SA, Matherly LH. Effects of the loss of capacity for N-glycosylation on the transport activity and cellular localisation of the human reduced folate carrier. Biochim Biophys Acta 1998; 1375: 6-12.
34. Haber M, Bordow SB, Gilbert J, Madafiglio J, Kavallaris M, Marshall GM, Mechetner EB, Fruehauf JP, Tee L, Cohn SL, Salwen H, Schmidt ML, Norris MD. Altered expression of the MYCN oncogene modulates MRP gene expression and response to cytotoxic drugs in neuroblastoma cells. Oncogene 1999; 18: 2777-2782.
35. Haber M, Reed C, Kavallaris M, Norris MD, Stewart BW. Resistance to drugs associated with the multidrug resistance phenotype following selection with high-concentration methotrexate. J Natl Cancer Inst 1989; 81: 1250-1254.
36. Matherly LH, Angeles SM, McGuire JJ. Determinants of the disparate antitumor activities of (6R)-5,10-dideaza-5,6,7,8-tetrahydrofolate and methotrexate toward human lymphoblastic leukemia cells, characterized by severely impaired antifolate membrane transport. Biochem Pharmacol 1993; 46: 2185-2195.
37. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-159.
38. Noonan KE, Beck C, Holzmayer TA, Chin JE, Wunder JS, Andrulis IL, Gazdar AF, Willman CL, Griffith B, Von Hoff DD, Roninson IB. Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci USA 1990; 87: 7160-7164.
39. Sirotnak FM, Tolner B. Carrier-mediated membrane transport of folates in mammalian cells. Annu Rev Nutr 1999; 19: 91-122.
40. Wong SC, Zhang L, Witt TL, Proefke SA, Bhushan A, Matherly LH. Impaired membrane transport in methotrexate-resistant CCRF-CEM cells involves early translation termination and increased turnover of a mutant reduced folate carrier. J Biol Chem 1999; 274: 10388-10394.
41. Matherly LH, Barlow CK, Goldman ID. Antifolate polyglutamylation and competitive drug displacement at dihydrofolate reductase as important elements in leucovorin rescue in L1210 cells. Cancer Res 1986; 46: 588-593.
42. Tse A, Moran RG. Cellular folates prevent polyglutamylation of 5,10-dideazatetrahydrofolate. J Biol Chem 1998; 273: 25944-25952.
43. Jackman AL, Taylor GA, Gibson W, Kimbell R, Brown M, Calvert AH, Judson IR, Hughes LR. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. Cancer Res 1991; 51: 5579-5586.